Principal Sum (Death Benefit)

The Principal Sum, also known as the Death Benefit, is the amount of money paid to the beneficiary of a life insurance policy upon the death of the insured. This is the amount agreed upon by the insured and the insurance company at the time the policy is issued.

For example, if the insured has a life insurance policy with a Principal Sum of $500,000, then the beneficiary will receive $500,000 upon the insured's death. The key features of Principal Sum (Death Benefit) in insurance are:

• Agreed amount: The Principal Sum is the agreed-upon amount between the insured and the insurance company at the time the policy is issued.

• Payment: The Principal Sum is paid to the beneficiary upon the death of the insured.

• Tax-free: The Principal Sum is typically paid out tax-free to the beneficiary.

• Policy cost: The cost of the insurance policy is typically based on the Principal Sum, with higher sums resulting in higher premiums.

• Flexibility: The Principal Sum can often be adjusted over time to accommodate changing needs or circumstances.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.